196 related articles for article (PubMed ID: 31768697)
41. PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
Pegram MD; Bondarenko I; Zorzetto MMC; Hingmire S; Iwase H; Krivorotko PV; Lee KS; Li RK; Pikiel J; Aggarwal R; Ewesuedo R; Freyman A; Li R; Vana A; Yin D; Zacharchuk C; Tan-Chiu E
Br J Cancer; 2019 Jan; 120(2):172-182. PubMed ID: 30568294
[TBL] [Abstract][Full Text] [Related]
42. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects.
Zhu X; Ding Y; Yu Y; Wang M; Zhou W; Wang J; Zhu X; Zhang H; Wang M; Chai K; Zhang X; Luk A; Jiang W; Liu S; Zhang Q
Cancer Chemother Pharmacol; 2021 Mar; 87(3):349-359. PubMed ID: 33169186
[TBL] [Abstract][Full Text] [Related]
43. AVAiLABLE NIS - AVASTIN® in lung cancer treatment in routine oncology practice in Germany.
Zahn MO; Linck D; Losem C; Gessner C; Metze H; Gaillard VE; Tessen HW
BMC Cancer; 2019 May; 19(1):433. PubMed ID: 31077164
[TBL] [Abstract][Full Text] [Related]
44. A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men.
Markus R; Chow V; Pan Z; Hanes V
Cancer Chemother Pharmacol; 2017 Oct; 80(4):755-763. PubMed ID: 28864922
[TBL] [Abstract][Full Text] [Related]
45. FKB238: A Bevacizumab Biosimilar.
Syed YY
Clin Drug Investig; 2021 Sep; 41(9):825-828. PubMed ID: 34347284
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial.
Rezvani H; Mortazavizadeh SM; Allahyari A; Nekuee A; Najafi SN; Vahidfar M; Ghadyani M; Khosravi A; Qarib S; Sadeghi A; Esfandbod M; Rajaeinejad M; Rezvani A; Hajiqolami A; Payandeh M; Shazad B; Anjidani N; Meskinimood S; Alikhasi A; Karbalaeian M; Salari S
Clin Ther; 2020 May; 42(5):848-859. PubMed ID: 32334845
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics, safety, tolerability, and immunogenicity of FKB238, a new biosimilar of bevacizumab, in healthy participants.
Boyce M; Wilkes D; Kaito H; Takanuma M; Arai Y
Int J Clin Pharmacol Ther; 2022 Jun; 60(6):280-290. PubMed ID: 35361328
[TBL] [Abstract][Full Text] [Related]
48. Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.
Cohen SB; Radominski SC; Kameda H; Kivitz AJ; Tee M; Cronenberger C; Zhang M; Hackley S; Rehman MI; von Richter O; Alten R
BioDrugs; 2020 Apr; 34(2):197-207. PubMed ID: 31939063
[TBL] [Abstract][Full Text] [Related]
49. Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
Gridelli C; de Castro Carpeno J; Dingemans AC; Griesinger F; Grossi F; Langer C; Ohe Y; Syrigos K; Thatcher N; Das-Gupta A; Truman M; Donica M; Smoljanovic V; Bennouna J
JAMA Oncol; 2018 Dec; 4(12):e183486. PubMed ID: 30177994
[TBL] [Abstract][Full Text] [Related]
50. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.
Waller CF; Vutikullird A; Lawrence TE; Shaw A; Liu MS; Baczkowski M; Sharma R; Barve A; Goyal P; Donnelly C; Sengupta N; Pennella EJ
Br J Clin Pharmacol; 2018 Oct; 84(10):2336-2343. PubMed ID: 29926514
[TBL] [Abstract][Full Text] [Related]
51. MYL-1402O: A Bevacizumab Biosimilar.
Lee A
Target Oncol; 2022 Jan; 17(1):85-88. PubMed ID: 34910269
[TBL] [Abstract][Full Text] [Related]
52. Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?
Tu CL; Wang YL; Hu TM; Hsu LF
BioDrugs; 2019 Aug; 33(4):437-446. PubMed ID: 31111423
[TBL] [Abstract][Full Text] [Related]
53. SB8: A Bevacizumab Biosimilar.
Syed YY
Target Oncol; 2020 Dec; 15(6):787-790. PubMed ID: 33206282
[TBL] [Abstract][Full Text] [Related]
54. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
55. Comparative assessment of pharmacokinetic parameters between HS016, an adalimumab biosimilar, and adalimumab (Humira®) in healthy subjects and ankylosing spondylitis patients: Population pharmacokinetic modeling.
Zeng X; Zhang J; Yu J; Wu X; Chen Y; Wu J; Yang X; Wang J; Cao G
Adv Clin Exp Med; 2022 May; 31(5):499-509. PubMed ID: 35148573
[TBL] [Abstract][Full Text] [Related]
56. Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer.
Socinski MA; Waller CF; Idris T; Bondarenko I; Luft A; Beckmann K; Vishweswaramurthy A; Loganathan S; Donnelly C; Hummel MA; Shapiro R; Woods M; Rao A; Nayak VG; Ranganna G; Barve A
Ther Adv Med Oncol; 2021; 13():17588359211045845. PubMed ID: 34819997
[TBL] [Abstract][Full Text] [Related]
57. Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis.
Xiao X; Zhang G; Sun B; Wang C; Wang X; Kong F; Jia Y
Transl Cancer Res; 2022 Jun; 11(6):1472-1482. PubMed ID: 35836506
[TBL] [Abstract][Full Text] [Related]
58. Production of monoclonal antibodies for measuring Avastin and its biosimilar by Sandwich ELISA.
Li M; An W; Wang L; Zhang F; Li J; Zhang Y; Li Y; Li H; Ren W; Zhao R; Xia C; Sun L
J Immunol Methods; 2019 Jun; 469():42-46. PubMed ID: 30943379
[TBL] [Abstract][Full Text] [Related]
59. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V
Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856
[TBL] [Abstract][Full Text] [Related]
60. Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)).
Hurst S; Ryan AM; Ng CK; McNally JM; Lorello LG; Finch GL; Leach MW; Ploch SA; Fohey JA; Smolarek TA
BioDrugs; 2014 Oct; 28(5):451-9. PubMed ID: 25001079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
